GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Ceftazidime

GlobalRPh source pageBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Professional source

UCSF - ceftazidime

Product / population
Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.
Renal measure
CrCl in mL/min where specified; no equation inferred.

Dosing / renal protocol and limits

Short-infusion IV dosing by CrCl: >50, 2 g every 8 hours; 31-50, 2 g every 12 hours; 15-30, 2 g daily; <15, 1 g daily.

IHD: 1 g initially and following each dialysis. CVVHD: 2 g every 12 hours.

A separate specialist-selected extended-infusion strategy uses 2 g over 30 minutes as loading, then maintenance beginning 4 hours later. Maintenance infusions last 4 hours: 2 g every 8 hours above CrCl 50 or every 12 hours at 31-50. Below 31, use short infusion. CVVHD extended infusion also requires ID/pharmacy selection.

Source revision: Revision date not stated in the reviewed page. | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://idmp.ucsf.edu/content/ceftazidime

Scope: Locally included source-specific summary. Regimen differences are not automatically resolved. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Professional guidance

UCSF - ceftazidime

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeUCSF - ceftazidime
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.
Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/ceftazidime/

Usual Dosing (Adults)

Usual: 1 to 2 grams IV every 8 to 12 hours. Severe: 2 grams IV every 8 hours.

Source dosing table:

IndicationDoseInterval
Usual adult1 g IV/IMEvery 8 to 12 hours
Uncomplicated urinary tract250 mg IV/IMEvery 12 hours
Bone and joint2 g IVEvery 12 hours
Complicated urinary tract500 mg IV/IMEvery 8 to 12 hours
Uncomplicated pneumonia or mild skin/skin structure500 mg to 1 g IV/IMEvery 8 hours
Serious gynecologic or intra-abdominal2 g IVEvery 8 hours
Meningitis2 g IVEvery 8 hours
Very severe life-threatening infections, especially immunocompromised2 g IVEvery 8 hours
Cystic fibrosis lung infection due to Pseudomonas with normal renal function30 to 50 mg/kg IV; maximum 6 g/dayEvery 8 hours
Neonates 0 to 4 weeks30 mg/kg IVEvery 12 hours
Infants and children 1 month to 12 years30 to 50 mg/kg IV; maximum 6 g/dayEvery 8 hours

The higher pediatric dose is for immunocompromised patients, cystic fibrosis, or meningitis. In cystic fibrosis patients clinical improvement has occurred, but bacteriologic cures cannot be expected in chronic respiratory disease and cystic fibrosis.

GRPH-ceftazidime-01 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

CrCl (mL/min)Dose
>50No change
31 to 501 g every 12 hours
16 to 301 g every 24 hours
6 to 15500 mg every 24 hours
<5 or dialysis500 mg every 48 hours

All renal doses may be increased by 50% in severe infections, as stated in the source.

GRPH-ceftazidime-02 · Source section: Renal DosingRenal section finder

Hemodialysis

1 g loading dose, then 1 g after each hemodialysis session. Alternative: 1 g every 48 hours plus 1 g after each hemodialysis.

CAPD: 1 g once, then 500 mg every 24 hours.

GRPH-ceftazidime-03 · Source section: HemodialysisRenal section finder
Separate professional-source layer

University and professional protocols

Professional

UCSF - ceftazidime

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Short-infusion IV dosing by CrCl: >50, 2 g every 8 hours; 31-50, 2 g every 12 hours; 15-30, 2 g daily; <15, 1 g daily.

IHD: 1 g initially and following each dialysis. CVVHD: 2 g every 12 hours.

A separate specialist-selected extended-infusion strategy uses 2 g over 30 minutes as loading, then maintenance beginning 4 hours later. Maintenance infusions last 4 hours: 2 g every 8 hours above CrCl 50 or every 12 hours at 31-50. Below 31, use short infusion. CVVHD extended infusion also requires ID/pharmacy selection.

RDM30-004-ceftazidime-1 · Source locator: UCSF - ceftazidime; renal/dosing sections and stated qualifiers

Source identity and provenance
Source
https://idmp.ucsf.edu/content/ceftazidime
Retrieved
2026-09-05
Renal-function method
CrCl in mL/min where specified; no equation inferred.
Source date/version
Revision date not stated in the reviewed page.
Hash meaning
Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256
3eb9c9538c9cdf800c1110f1375ef9df2a84c767329b4f85b38f28507a9c93c3

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 0 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/ceftazidime/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
cc0ba54d22ad755d40787a7e30557907c12a60ffe42806901efa0f90196a05f2
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report